Literature DB >> 55838

Efficacy of prophylactic gamma-globulin in preventing non-A, non-B post-transfusion hepatitis.

R G Knodell, M E Conrad, A L Ginsberg, C J Bell.   

Abstract

Of 279 cardiac-surgery patients receiving a mean of twelve transfusions, 47 had significantly increased transaminase concentrations 14 to 180 days postoperatively and 10 were icteric. Preoperatively, each patient randomly received high-titre HbsAb gamma-globulin, normal gamma-globulin, or placebo and was followed at intervals for 9 months. Only 3 patients had serological evidence of hepatitis-B infection. 3 additional patients had serological evidence of cytomegalovirus infection, while none had evidence of hepatitis-A or Epstein-Barr infection. Less icteric hepatitis occurred in patients receiving the gamma-globulin preparations (P = 0-003), and the overall frequency of hepatitis was significantly reduced when compared with recipients of placebo. The protective effects of the two gamma-globulin preparations were not significantly different. Most post-transfusion hepatitis tody is neither viral hepatitis type B nor type A, and its severity and transmission are reduced by pre-transfusion gamma-globulin.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 55838     DOI: 10.1016/s0140-6736(76)90357-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  19 in total

Review 1.  Passive immunity in prevention and treatment of infectious diseases.

Authors:  M A Keller; E R Stiehm
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

2.  Internal medicine: non-a, non-B hepatitis.

Authors:  G Garcia
Journal:  West J Med       Date:  1985-07

3.  Non-A non-B hepatitis.

Authors: 
Journal:  Br Med J       Date:  1978-04-15

4.  Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitis C virus.

Authors:  Jean-Christophe Meunier; Judith M Gottwein; Michael Houghton; Rodney S Russell; Suzanne U Emerson; Jens Bukh; Robert H Purcell
Journal:  J Infect Dis       Date:  2011-10-15       Impact factor: 5.226

5.  HCV antibody response and genotype distribution in different areas and races of China.

Authors:  Leili Jia; Jiyun Yu; Jinliang Yang; Hongbin Song; Xuelin Liu; Yong Wang; Yuanyong Xu; Chuanfu Zhang; Yanwei Zhong; Qiao Li
Journal:  Int J Biol Sci       Date:  2009-06-13       Impact factor: 6.580

Review 6.  Managing occupational risks for hepatitis C transmission in the health care setting.

Authors:  David K Henderson
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

7.  Prospective study of post-transfusion hepatitis after cardiac surgery in a British centre.

Authors:  J D Collins; M F Bassendine; A A Codd; A Collins; R E Ferner; O F James
Journal:  Br Med J (Clin Res Ed)       Date:  1983-11-12

8.  Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma.

Authors:  Mei-ying W Yu; Birke Bartosch; Pei Zhang; Zheng-ping Guo; Paula M Renzi; Li-Ming Shen; Christelle Granier; Stephen M Feinstone; François-Loïc Cosset; Robert H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-10       Impact factor: 11.205

9.  Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus.

Authors:  Jean-Christophe Meunier; Rodney S Russell; Vera Goossens; Sofie Priem; Hugo Walter; Erik Depla; Ann Union; Kristina N Faulk; Jens Bukh; Suzanne U Emerson; Robert H Purcell
Journal:  J Virol       Date:  2007-10-31       Impact factor: 5.103

10.  Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein.

Authors:  Ania M Owsianka; Alexander W Tarr; Zhen-Yong Keck; Ta-Kai Li; Jeroen Witteveldt; Richard Adair; Steven K H Foung; Jonathan K Ball; Arvind H Patel
Journal:  J Gen Virol       Date:  2008-03       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.